This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (45)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bullous Diseases  • Pemphigus  • Immunotherapy  • Genetics  • Genetic Disorders  • Immunologic Disorders  • Alert me on articles by topic

A. Razzaque Ahmed, MD, DSc; Mark V. Dahl, MD; for the Consensus Development Group

Arch Dermatol. 2003;139:1051-1059.

Objectives  The purpose of the meeting of the Consensus Development Group was to critically evaluate the current published data on the use of intravenous immunoglobulin (IVIg) therapy in the treatment of autoimmune mucocutaneous blistering diseases (AMBDs) and to discuss the industrial preparation and safety features of this biologic agent.

Participants  The participants were physicians who frequently treat patients with these diseases and included dermatologists, oral medicine specialists, ophthalmologists, and immunologists. The members of the group provided input and discussion in their areas of expertise. The participants were invited attendees.

Evidence  Data samples included only published information in the English-language literature. The expert opinions and experience of the members of the Consensus Development Group were vital to the discussion.

Consensus Process  A consensus was achieved by an open discussion and cumulative agreement on all issues relevant to the use of IVIg therapy in the treatment of AMBDs. Special emphasis was placed on indications for its use, determination of outcome parameters, and development of a protocol for its therapeutic use. We also focused on its safety and on prevention of adverse effects.

Conclusion  This consensus statement outlines the scope of IVIg treatment; provides guidelines for its use, including indications, prescreening, premedications, dose, frequency, and monitoring; and defines the end point of therapy.

From the Department of Dermatology and Oral Medicine, Harvard Medical School and Harvard School of Dental Medicine, Boston, Mass (Dr Ahmed); and Department of Dermatology, Mayo Clinic, Scottsdale, Ariz (Dr Dahl). The authors have no relevant financial interest in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Unlabeled uses of intravenous immune globulin
Leong et al.
Am J Health Syst Pharm 2008;65:1815-1824.
ABSTRACT | FULL TEXT  

Frequency of Adverse Events Associated with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid
Gurcan and Ahmed
The Annals of Pharmacotherapy 2007;41:1604-1610.
ABSTRACT | FULL TEXT  

A Single Cycle of Rituximab for the Treatment of Severe Pemphigus
Joly et al.
NEJM 2007;357:545-552.
ABSTRACT | FULL TEXT  

Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders
Gurcan and Ahmed
The Annals of Pharmacotherapy 2007;41:812-823.
ABSTRACT | FULL TEXT  

Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin
Ahmed et al.
NEJM 2006;355:1772-1779.
ABSTRACT | FULL TEXT  

Cost of Intravenous Immunoglobulin Therapy Versus Conventional Immunosuppressive Therapy in Patients with Mucous Membrane Pemphigoid: A Preliminary Study
Daoud et al.
The Annals of Pharmacotherapy 2005;39:2003-2008.
ABSTRACT | FULL TEXT  

Involvement of the Female Genital Tract in Pemphigus Vulgaris
Malik and Ahmed
Obstet Gynecol 2005;106:1005-1012.
ABSTRACT | FULL TEXT